Creatd Completes Purchase of 25% of PCG Advisory for $1.25 Million

Stock Information for Bellerophon Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Bellerophon Therapeutics Inc.

Flyte, Inc. Expands Vision Jet Fleet to Support 2026 Growth Strategy
Creatd, Inc. Reports Record EPS, Up 75% YoY; Net Equity Surpasses $9 Million
Creatd, Inc. Engages Dawson James Securities, Inc. and Lucosky Brookman, LLP to Execute Uplisting Strategy
Creatd to File Quarterly Financials on Friday, November 14; Schedules Investor Conference Call for Monday, November 17 at 4:30 PM ET
Creatd Launches Flyte Escapes: AI-Enhanced Luxury Travel Experiences for the Modern Era
Creatd, Inc. Approved to Trade on the OTCQB Venture Market with Nearly $10 Million in Positive Net Equity
Creatd's Flyte Positions for Strategic Expansion Following Verijet Bankruptcy
Creatd, Inc. Files S-1 Registration Statement with SEC, Signaling Readiness for Future National Exchange Uplisting

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.